Combined clinical effect of amikacin and cefoxitin in patients with severe infections complicated by hematological diseases

Uno, N.; Nosaka, T.; Uchiyama, S.; Kawakami, K.; Hoshino, K.; Mori, M.; Hotta, Y.; Ohta, C.; Kobayashi, T.; Kita, K.

Japanese Journal of Antibiotics 40(3): 469-475

1987


ISSN/ISBN: 0368-2781
PMID: 3613072
Document Number: 301056
A clinical investigation was made on the concurrent use of amikacin (AMK) and cefoxitin (CFX) against complicated infections with hematological disorders. The results obtained were summarized as follows: Eleven patients were treated with AMK and CFX. Clinical responses were excellent in 2 (18%), good in 4 (36%), fair in 1 (9%), and poor in 4 (36%), with an efficacy rate of 64%. No significant side effects requiring cessation of the treatment were observed.

Document emailed within 1 workday
Secure & encrypted payments